How these IPOs fared 1 week later

This is how the latest shares listing on the ASX performed.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first week of a company being on the ASX boards can be very telling. The market doesn't get any new information until the next quarterly or half-year result, so we can get a sense of the market sentiment from how the share does in its first week.

Of course, how the market treats a share doesn't ultimately mean anything. But, it can be interesting nonetheless.

Here are how the latest ASX shares fared:

Constellation Resources Limited (ASX: CR1)

This company is a resource exploration business. It holds the Orpheus Project, which comprises five tenements covering approximately 552km² in a prospective portion of the Fraser Range province of Western Australia. The region could have nickel, copper and gold after a discovery in 2012.

It was looking to raise money at $0.20 per share and it's currently trading at $0.305, which shows a quick 52% return.

Tempus Resources Ltd (ASX: TMR)

Tempus is also a resource exploration business. It has a 90% interest in a business which is the registered holder of the Montejinni Project in the Northern Territory and the Claypan Dam Project in South Australia. Its focus will be looking for copper but it will also look for other resources.

It was also looking to start trading on 30 July 2018, but it appears to not have made it onto the boards. There is no new expected listing date according to the ASX.

Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)

It's a biopharmaceuticals business. It is developing peptide-based pharmaceutical products that target a number of neurological disorders that have high unmet medical needs. The current R&D program is focused on developing a treatment for stroke-related brain injury and dementia / Alzheimer's disease, and a diagnostic for early-stage Alzheimer's disease.

It was looking to raise money at $0.20 per share and it's now trading at $0.25 per share, showing a quick 25% gain since listing last week.

Foolish takeaway

If I had to invest in one share it would be Neuroscientific Biopharmaceuticals as I'm really not a fan of resource shares in general. However, they are all too speculative for me, so I'm personally going to invest in other things.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

A man slumps crankily over his morning coffee as it pours with rain outside.
Gold

Why is this ASX gold share crashing 22% today?

Let's find out why this gold miner is down in the dumps on Tuesday.

Read more »

Man with his hand out, symbolising a trading halt.
Technology Shares

Why is the Appen share price frozen today?

This high-flying AI stock has requested a trading halt this morning.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Capital Raising

Guess which ASX 300 copper stock is crashing 12% today

Let's see what is causing this stock to sink deep into the red.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Capital Raising

Why is this ASX 300 stock crashing 18% today?

Let's see what is making investors hit the sell button today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX All Ords stock sinking 14% on Friday?

Let's see why investors hitting the sell button today.

Read more »

Data Centre Technology
Capital Raising

NextDC share price drops on $750m capital injection for Asian expansion

The data centre operator is raising funds to support its expansion.

Read more »

Kid stacking coins from the jar.
Capital Raising

This ASX 300 stock is rising after completing its next step for Canadian growth

Expanding in Canada could be a patently good idea.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Capital Raising

Guess which ASX All Ords stock is leaping 9% after raising $60 million

This fast-growing company is maintaining a lean balance sheet while making an accretive acquisition.

Read more »